These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 3359703

  • 1. Urinary cross-linked fibrin degradation products in glomerular disease with crescents.
    Kamitsuji H, Matsunaga K, Taira K, Nakajima M, Whitworth JA, Kincaid-Smith P.
    Clin Nephrol; 1988 Mar; 29(3):124-8. PubMed ID: 3359703
    [Abstract] [Full Text] [Related]

  • 2. [Urinary cross-linked FDP in various renal diseases].
    Inuma H.
    Nihon Jinzo Gakkai Shi; 1994 Feb; 36(2):146-57. PubMed ID: 8139147
    [Abstract] [Full Text] [Related]

  • 3. Urinary crosslinked fibrin degradation products in glomerular disease.
    Kamitsuji H, Whitworth JA, Dowling JP, Kincaid-Smith P.
    Am J Kidney Dis; 1986 Jun; 7(6):452-5. PubMed ID: 3717150
    [Abstract] [Full Text] [Related]

  • 4. [Significance of urinary fibrin/fibrinogen degradation products (FDP) measured by highly sensitive ELISA method in various renal diseases].
    Shibata T, Sumie A, Ishii T, Tomo T, Magari Y, Sato J, Yasumori R, Nasu M.
    Nihon Jinzo Gakkai Shi; 1993 Jun; 35(6):687-94. PubMed ID: 8377281
    [Abstract] [Full Text] [Related]

  • 5. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL, Francis CW, Knutson DW, Marder VJ.
    J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
    [Abstract] [Full Text] [Related]

  • 6. Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis.
    Michielsen P, Roels L, Vanrenterghem Y, Boel A, van Damme B, Vermylen J.
    Clin Nephrol; 1976 Mar; 5(3):105-13. PubMed ID: 1261101
    [Abstract] [Full Text] [Related]

  • 7. Urinary platelet factor four (Pf4) levels in mesangial IgA glomerulonephritis and thin basement membrane disease.
    Taira K, Hewitson TD, Kincaid-Smith P.
    Clin Nephrol; 1992 Jan; 37(1):8-13. PubMed ID: 1541068
    [Abstract] [Full Text] [Related]

  • 8. [Clinical significance of urinary fibrin/fibrinogen degradation products in renal disease. First report: Urinary fibrin/fibrinogen degradation products in primary glomerulonephritis (author's transl)].
    Miyamura S.
    Nihon Jinzo Gakkai Shi; 1978 Jan; 20(1):67-78. PubMed ID: 650992
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical implication of urine test for markers of endothelial dysfunction and angiogenesis factors in assessment of tubulointerstitial fibrosis in chronic glomerulonephritis].
    Bobkova IN, Kozlovskaia LV, Rameeva AS, Varshavskiĭ VA, Golitsyna EP.
    Ter Arkh; 2007 Jan; 79(6):10-5. PubMed ID: 17684960
    [Abstract] [Full Text] [Related]

  • 10. Two distinct types of crescentic glomerulonephritis.
    Takeda S, Kida H, Yokoyama H, Tomosugi N, Kobayashi K.
    Clin Nephrol; 1992 Jun; 37(6):285-93. PubMed ID: 1638779
    [Abstract] [Full Text] [Related]

  • 11. [Urinary excretion of fibrin degradation products in children with nephrotic syndrome (author's transl)].
    Bouissou F, Barthe P, Boneu B.
    Arch Fr Pediatr; 1980 Mar; 37(3):167-71. PubMed ID: 7469695
    [Abstract] [Full Text] [Related]

  • 12. [Determination of urinary fibrin-fibrinogen degradation products (FDP) in various infantile glomerular nephorapathies].
    Tamborine G, Barbieri U, Forese S, Cocconcelli P, Zervos N.
    Minerva Pediatr; 1977 Mar 10; 29(8):525-8. PubMed ID: 865431
    [No Abstract] [Full Text] [Related]

  • 13. Fragments of urinary fibrin/fibrinogen degradation products and cross-linked fibrin degradation products in various renal diseases.
    Taira K, Matsunaga T, Kawahara S, Sakamoto S, Kamitsuji H.
    Thromb Res; 1989 Feb 15; 53(4):367-77. PubMed ID: 2929008
    [Abstract] [Full Text] [Related]

  • 14. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
    Shibata T, Magari Y, Kamberi P, Ishii T, Tomo T, Yasumori R, Nasu M.
    Clin Nephrol; 1995 Aug 15; 44(2):91-5. PubMed ID: 8529315
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantitative morphometry of glomerulonephritis with crescents. Diagnostic and predictive value.
    Elfenbein IB, Baluarte HJ, Cubillos-Rojas M, Gruskin AB, Coté M, Cornfeld D.
    Lab Invest; 1975 Jan 15; 32(1):56-64. PubMed ID: 1113503
    [Abstract] [Full Text] [Related]

  • 20. Urinary fibrinogen degradation products and differential protein clearances in renal disease.
    Blainey JD, Terry JM.
    Clin Nephrol; 1979 Mar 15; 11(3):140-1. PubMed ID: 436342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.